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The CD4+CD25+ lineage of regulatory T (Treg)
cells plays a key role in controlling immune
and autoimmune responses and is character-
ized by a unique transcriptional signature. The
transcription factor Foxp3 had been thought
to determine the Treg cell lineage, a hypothesis
challenged by recent observations. We have
performed a cross-sectional analysis of the
Treg cell signature in Treg-like cells generated
under a number of conditions, with or without
Foxp3, to delineate the elements that can be
ascribed to T cell activation, interleukin-2,
transforming growth factor-b (TGF-b) signaling,
or Foxp3 itself. These influences synergized to
determine many of the signature’s compo-
nents. Much of the Treg cell signature was not
ascribable to Foxp3 because it contained
gene clusters that are coregulated with, but
not transactivated by, Foxp3. Thus, a higher
level of regulation upstream of Foxp3 deter-
mines the lineage, distinct from elements
downstream of Foxp3 that are essential for its
regulatory properties.
INTRODUCTION
CD4+ regulatory T (Treg) cells are central to the mainte-
nance of immunological tolerance (Sakaguchi et al.,
2006). This subset was initially identified as CD25+CD4+
T cells capable of controlling autoimmunity provoked by
neonatal thymectomy or lymphopenia-induced dysregu-
lation (Sakaguchi et al., 1995). Later, such cells were found
to express the forkhead-winged helix transcription factor,
Foxp3 (Khattri et al., 2003; Fontenot et al., 2003; Hori et al.,
2003). Deficiencies in Foxp3 underlie the devastating lym-
phoproliferation and multiorgan autoimmunity in Scurfy
mutant mice and human patients with the immunodysre-786 Immunity 27, 786–800, November 2007 ª2007 Elsevier Incgulation, polyendocrinopathy, and enteropathy, X linked
(IPEX) syndrome (Ziegler, 2006).
In the hematopoietic system, as elsewhere, differentia-
tion into a particular lineage is thought to be determined by
one or a combination of lineage-specification factors
(Aliahmad and Kaye, 2006). In many instances, these line-
age-committing factors integrate with the pre-established
genomic terrain to produce a particular cellular phenotype
or function (Souabni et al., 2002; Sun et al., 2005; He et al.,
2005; Laiosa et al., 2006). In other cases, a factor (for ex-
ample C/EBPa and b) can appear to be necessary and
sufficient for determining a lineage (Xie et al., 2004; Laiosa
et al., 2006). It has often been stated that Foxp3 acts as
the ‘‘master regulator’’ or ‘‘lineage-specification factor’’
for Treg cells (Fontenot et al., 2005), because of the pro-
found consequences of its absence and because ectopic
expression of Foxp3 in CD4+ T cells generates a popula-
tion with functional and phenotypic similarities to natural
Treg cells (Hori et al., 2003). In contrast, several studies
have hinted that Foxp3 might not have such a central
role in determining the Treg cell lineage. A genomic anal-
ysis of Foxp3-transduced cells suggested that some
elements of the Treg signature might be independent of
this transcription factor (Sugimoto et al., 2006). More di-
rectly, cells with some, but not all, of the features of the
Treg cell lineage are found in mice wherein the function
of Foxp3 was inactivated but transcriptional activity at
the locus remained detectable (Gavin et al., 2007; Lin
et al., 2007).
A distinct gene-expression signature characterizes
Foxp3+ Treg cells (Fontenot et al., 2005; Huehn et al.,
2004; Herman et al., 2004). It includes not only certain
cell-surface receptors long recognized as hallmarks of
the lineage but also a wider array of transcription factors
and other intracellular proteins. To elucidate the origin
and determinism of this signature, and to clarify the impor-
tance of Foxp3 in specifying the Treg lineage, we have
performed a cross-sectional analysis of the Treg tran-
scriptional signature by combining gene-expression
profiles from Treg cells obtained under many different
conditions, by employing various inducers, and in the
presence or absence of Foxp3. We have addressed the
transcriptional impact of T cell activation through T cell.
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Regulatory T Cell Transcriptional SignatureFigure 1. Populations of T Cells Used for Defining the Common Treg Cell Signature
(A) Summary of sorted populations used for analysis (the group names are used throughout).
(B and C) Depth of the Treg cell signature, estimated by ranked juxtaposition of independent Treg versus Tconv comparisons. (B) shows the mean fold
change in the spleen Treg to Tconv comparison (black dots), in sliding windows ranked by fold change in the lymph node comparison (red dots). (C)
shows the significance of the fold-change bias in the indicator comparison for the same sliding windows; the p = 0.05 threshold for significance is
shown as a horizontal line.receptor (TCR), interleukin-2 (IL-2), and transforming
growth factor-b (TGF-b) signaling, as well as the influence
of ectopic Foxp3 expression in conventional T cells. The
combined data allowed the delineation of coregulated
gene clusters within the Treg cell signature, thereby pro-
viding a new perspective on the determinism of the line-
age, the interplay between Foxp3 and TGF-b or IL-2,
and the notion that a higher level of regulation actually
determines the Treg cell lineage.
RESULTS
Defining the Treg Cell Signature
To define the components and origin of the Treg cell sig-
nature, we performed a meta-analysis that combined
gene-expression profiles, generated in several parallelImexperiments, from Treg cells or other Foxp3+ cells. As
will be discussed below, the datasets listed in Figure 1A
reflected a set of focused comparisons (e.g., the impact
of TGF-b or the comparison of thymic and peripheral
Treg cells), but their joint analysis also allowed a broader
perspective on the Treg cell signature and its origin. In ad-
dition, we imported several relevant published datasets:
comparative profiles from Treg and conventional T (Tconv)
cells performed elsewhere (Fontenot et al., 2005; Gavin
et al., 2007; Lin et al., 2007), a list of IL-2-responsive genes
(Verdeil et al., 2006), and lists of Foxp3-binding genomic
loci generated by chromatin immunoprecipitation (Zheng
et al., 2007; Marson et al., 2007).
All gene-expression profiles were obtained from highly
purified T cell populations sorted by flow cytometry. Pop-
ulations used for in vitro activation were derived from naivemunity 27, 786–800, November 2007 ª2007 Elsevier Inc. 787
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neous influences resulting from prior cell activation. To
reduce variability, we pooled cells from multiple mice for
sorting, and three replicates were generated for all groups.
RNA from 0.5 to 2.5 3 105 cells was amplified, labeled,
and hybridized to Affymetrix M430v2 microarrays that
cover the quasi-totality of known murine genes. Raw
data were preprocessed with the RMA algorithm in Gene-
Pattern (Reich et al., 2006), and averaged expression
values were used for analysis (full datasets deposited at
NCBI under accession #GSE7460).
We first sought to obtain a comprehensive perspective
on the Treg cell transcriptional signature. It has been diffi-
cult to decipher the true extent of differential gene expres-
sion in pairwise comparisons (Allison et al., 2006).
Arbitrary cutoffs are often set on fold change or some
statistical metric corresponding to false-discovery rates
(FDRs) (Smyth, 2004) subjectively deemed acceptable;
yet such strategies leave out a substantial fraction of the
true but subtle differences that fail to meet this threshold.
To circumvent this difficulty, we used a computational ap-
proach that tests for significance by determining whether
differences observed in one experimental pair reproduce
across independent comparisons that involve the same
variable (here, the Treg versus Tconv cell difference; see
Experimental Procedures in the Supplemental Data avail-
able online for detailed description). Here, we used three
independently generated pairs of Treg-Tconv datasets
(one data pair from the lymph node and two independent
pairs from spleen; Figure 1A, groups 1–4, each group in
triplicate). As expected, specific changes were found on
both ends of the spectrum, with transcripts both overrep-
resented and underrepresented in Treg cells compared to
Tconv cells (Figure 1B). According to this analysis, the full
range of changes in Treg cells involved a larger number of
genes than previously recognized: Marked overexpres-
sion in Treg cells was detected for up to 1583 genes
down to subtle fold changes of 1.13 (or 1804 genes
deep for underexpressed genes at a fold change of 0.87
or less) (Figure 1C). Thus, the ‘‘identity’’ of Treg cells in-
volves very subtle changes in regulatory programs for
a wide number of genes.
In the analyses reported below, it was not possible to
track the full extent of the transcriptional characteristics
of Treg cells because this would involve changes at high
FDR in any single comparison. For a robust definition of
the transcriptional signature of mature Treg cells, we
brought together results from several independent exper-
iments: three profiles of lymph node and spleen Treg cells
obtained here and one profile from an independent labora-
tory (Fontenot et al., 2005). We compiled the consensus
peripheral Treg cell signature by calculating the Treg to
Tconv fold change (Fc) ratios in the four analyses and
retaining only those genes that showed a consistent
1.5-fold overexpression or underexpression in Treg cells
in all four datasets (603 genes overall; 407 and 196 over-
expressed or underexpressed in Treg cells, respectively;
identities, values, and cluster for this gene are listed in
Table S1).788 Immunity 27, 786–800, November 2007 ª2007 Elsevier IncAcquisition of the Treg Cell Signature
The Treg cell signature is defined, here and in other stud-
ies, on the basis of comparative gene-expression profiles
from mature Treg cells isolated from peripheral lymphoid
organs, such as the spleen or lymph node. It was of inter-
est to know how much of the Treg cell profile is acquired
early in the life history of these cells versus what might re-
sult from further maturation or other peripheral influences.
Thus, we performed parallel comparisons of Treg cells
and their Tconv counterparts isolated from the thymus,
spleen, or lymph node. Highlighting in color the transcripts
of the peripheral Treg cell signature defined above (over-
expressed and underexpressed genes, red and blue, re-
spectively) over the comparison of thymic Treg versus
Tconv cells (Figure 2A) revealed that the vast majority of
the signature’s differential elements were already present
in the thymus. This conclusion was confirmed in the ‘‘vol-
cano plot’’ (fold change versus t test p value) of Figure 2B,
which further emphasized the skewing of genes of the
common Treg cell signature: In total, 395/407 of the tran-
scripts overrepresented in mature Treg cells were also
overrepresented in thymic Treg cells (c2 p < 1050); 185/
196 were underrepresented. The differences found in
comparisons of thymic and peripheral Treg cells were
rather generic, in that they were evident also in compari-
sons of thymic and peripheral conventional CD4+ T cells
(Figures S1A and S1B). Note that a simple Venn diagram
comparison, analogous to that performed by Zheng
et al. (2007), shows an overlap of 79% between genes up-
regulated in thymic and peripheral Treg cells relative to
their Tconv counterparts (data not shown). Thus, most of
the Treg cell signature is already specified at an early
stage of lineage commitment, independent of peripheral
influences.
A Component of the Treg Cell Signature Is Related
to Activation
Many of the cell-surface molecules, prototypical exam-
ples being CD25 (Il2ra), CTLA-4 (Ctla4), and GITR
(Tnfrsf18) (Sakaguchi et al., 2006), expressed by periph-
eral Treg cells are also influenced by activation, a charac-
teristic that hampered convincing identification of the Treg
cell population for some time. This overlay might be due in
part to the capacity of Treg cells to actively cycle in vivo
(Fisson et al., 2003) and/or to the inherent self-reactivity
of their TCR (Hsieh et al., 2004). To determine the contri-
bution of mere activation to the Treg cell phenotype, we
compared the signature of mature Treg cells with the
changes elicited during T cell activation. The transcrip-
tional changes occurring during T cell activation encom-
pass those directly dependent on TCR (and costimulatory
molecule) engagement, as well as those elicited second-
arily by growth factors such as IL-2. To best encompass
both types of signals, we generated datasets from two
types of activated CD4+ T cells; first, we used CD4+ T cells
activated in vivo by cognate antigen (cells from an AND
TCR transgenic mouse, taken 60 hr after transfer into
hosts that express the moth cytochrome c peptide recog-
nized by the AND receptor [Obst et al., 2007]); second, to.
Immunity
Regulatory T Cell Transcriptional SignatureFigure 2. The Treg Cell Signature Is Imparted Early during Ontogeny and Contains Components of the Tconv Activation Response
(A) Comparison of expression values in Treg versus Tconv thymocytes, with the common signature of mature Treg cells highlighted in red (upregu-
lated transcripts) and blue (downregulated transcripts).
(B) ‘‘Volcano plot’’ representation (fold change versus t test p value) between Treg and Tconv cell expression profiles, restricted to the genes of the
common Treg cell signature.
(C) Fold change versus fold change (FcFc) plot comparing the effect of in vivo activation of CD4+ T cells with the Treg cell signature (ratio of spleen Treg
to Tconv).
(D) As in (C), but the y axis represents changes elicited in naive CD4+ T cells activated in vitro in the presence of IL-2.
(E) Same comparison as in (C), with IL-2-responsive genes defined from the data of Verdeil et al. (2006) highlighted in red.
(F) FcFc plot comparing the Treg signature before and after in vitro activation.ensure maximum activation and full IL-2 signaling, we
used CD4+ T cells activated in vitro with beads coupled
with anti-CD3 plus anti-CD28, supplemented with IL-2.
For the most part, the many changes elicited by activationImof CD4+ T cells bore no relationship to the Treg cell signa-
ture, as reflected by the predominant orthogonal streaks
in Figures 2C and 2D. However, a distinct component of
the transcripts responsive to either or both modes ofmunity 27, 786–800, November 2007 ª2007 Elsevier Inc. 789
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diagonal quadrants in Figures 2C and 2D; 232/407 and
136/196 of the overexpressed or underexpressed Treg
signature genes, at a 1.5-fold cutoff for activation-induced
changes). The Treg cell signature genes that overlapped
with an activation response represented a distinct subset
of the full activation response, primarily related to signal
transduction rather than cell cycle, as shown by gene-on-
tology analysis (30, 50 cyclic-nucleotide phosphodiester-
ase, Rab GTPase binding, and transmembrane receptor
protein serine-threonine kinase activity; c2 p < 0.01).
Thus, the Treg cell signature does include a large compo-
nent related to T cell activation, but this component is a
selective subset of the full response normally elicited by
T cell activation.
To confirm the influence of IL-2, we superimposed on
the same comparison of changes a list of IL-2-induced
genes, generated by Verdeil and colleagues in an analysis
of IL-2 effects in synergy with TCR engagement (Verdeil
et al., 2006) (Figure 2E). Essentially all of these IL-2-re-
sponsive genes showed a biased representation, by being
overexpressed to some extent in Treg cells compared
with Tconv cells activated in vivo.
Conversely, it was of interest to determine to what ex-
tent the distinctive transcriptional signature of Treg cells
would be affected by full activation. Naive Treg and Tconv
CD4+ cells were activated in vitro by anti-CD3 and anti-
CD28 beads with IL-2, and the Treg-Tconv differential ex-
pression profile compared before and after activation
(Figure 2F). Overall, the general distribution of genes along
the diagonal indicated that much of the Treg cell signature
persisted after TCR-mediated activation. However, close
to 30% of the common Treg cell signature was lost during
activation; this includes many candidate inhibitory recep-
tors and transcripts associated with anergy, such as
Klrg1, Itgb8, Cd200, Maf, Folr4 (Folate receptor 4), and
Egr2. Thus, certain elements of the Treg cell signature
are related to T cell activation, whereas other elements
of the signature are lost during Treg cell activation.
TGF-b Influences a Discrete Subset of the Treg
Cell Signature
TGF-b signaling plays a role in maintaining Treg cell
homeostasis, particularly in the periphery (Li et al.,
2006). In addition, this growth factor can induce Foxp3
expression and might confer suppressive properties on
CD4+ Tconv cells (Chen et al., 2003a; Fantini et al.,
2004; Wan and Flavell, 2005). One might expect, then,
that the TGF-b signaling pathway somehow contributes
to the Treg cell signature. In order to parse out such a con-
tribution, we generated gene-expression datasets from
naive CD25CD4+ Tconv cells cultured with anti-CD3
anti-CD28 beads in the presence of TGF-b and IL-2. Intra-
cellular staining showed that >90% of cells became
Foxp3+ at comparable amounts with that of Treg cells
(Figure 3A), beginning in the first 24 hr of culture (data
not shown). The profiles obtained with or without TGF-b
were compared with the common Treg cell signature.
The fold-change comparison of Figure 3B revealed that790 Immunity 27, 786–800, November 2007 ª2007 Elsevier Inc.TGF-b treatment elicited a number of the Treg signature
transcripts, but not all of them. Some of the canonical
Treg genes were induced, such as Foxp3 (as expected
from the cytometry profiles),Nrp1, Itgae, andGpr83. How-
ever, TGF-b did not enhance the expression of several
other Treg cell transcripts, such as Il2ra, Socs2, Tnfrsf18,
and Ctla4, despite the nearly uniform and high expression
of Foxp3 in the stimulated cells. One might argue that
TGF-b was having a negative influence on the transcrip-
tion of these genes by Foxp3; however, this was not the
case because Treg cells cultured in the same conditions
still exhibited the vast majority of the Treg signature
(Figure 3C). A large number of transcripts with no relation
to the Treg signature were also uniquely regulated by
TGF-b: At a fold-change cutoff of 1.5, 970 and 845 genes
were induced or repressed by TGF-b, of which only 123
and 72 belong to the canonical Treg cell signature. Thus,
TGF-b readily induced Foxp3 in cultured naive T cells
but influenced only a fraction of the transcriptional profile
normally associated with Treg cells. This disjunction
prompted us to test whether these TGF-b-induced cells
exhibited the usual suppressive properties of Treg cells.
This was clearly not the case, as illustrated in Figures 3D
and 3E: Suppression in the classic in vitro test (Thornton
and Shevach, 1998) was very limited, with a partial effect
visible only at high suppressor to target ratios (Figure 3D).
This poor suppressive ability was observed in a number of
experiments, in several different culture conditions and at
different times of culture, with bead or plate-coated anti-
CD3 plus anti-CD28 or with peptide stimulation in the
presence of splenic antigen-presenting cells (data not
shown). In addition, TGF-b-induced Foxp3+ cells were un-
able to confer protection against diabetes in vivo upon
cotransfer with diabetogenic effector T cells, again unlike
true Treg cells (Figure 3E). Thus, although TGF-b signaling
generates components of the Treg cell signature including
Foxp3, the full repertoire of transcripts and functional
characteristics are not observed.
Foxp3 Profoundly Affects the TGF-b Response
in CD4+ T Cells
The fact that a fraction of the Treg cell signature could be
mimicked by TGF-b led us to ask the converse question:
To what extent does Foxp3 participate in the response to
TGF-b in CD4+ T cells? Because TGF-b is a strong immu-
nomodulator in its own right, one might hypothesize that
Foxp3 makes some contribution to its effect in T cells.
We explored this question by examining CD4+ T cells
from the Scurfy mutant mice, which harbor a frameshift
mutation in the Foxp3 gene (Ziegler, 2006). Foxp3sf
mice usually develop a dramatic lymphoproliferative
autoimmune phenotype, but the presence of TCR trans-
genes such as those encoding the BDC2.5 TCR predom-
inantly prevented it, particularly in young mice (data not
shown). The use of 10-day-old mice in combination with
the TCR transgenes minimized the potentially confound-
ing effects of inflammation on the TGF-b response; in-
deed, flow-cytometric analysis prior to culture showed
negligible background activation in CD4+ T cells from
Immunity
Regulatory T Cell Transcriptional SignatureFigure 3. TGF-b Does Not Recapitulate the Entire Treg Cell Signature Despite Inducing Foxp3
(A) Foxp3 expression in TGF-b-treated cultures of naive CD4+ T cells, with cultured Treg cells for comparison (data representative of cytometry plots in
postsort populations used for microarray analysis; the mean percentage of Foxp3+ ± SD shown for three independent experiments and representative
mean fluorescence intensity [MFI].
(B) FcFc plot comparing changes induced by TGF-b in anti-CD3 and anti-CD28 + IL-2-activated T cells versus the Treg cell signature (Treg to Tconv
ratio).
(C) Fold change versus p value plot of the effect of TGF-b for Treg cell signature genes.
(D) In vitro inhibition assay in which ex vivo-isolated Treg cells or in vitro-activated Tconv cells cultured in the presence or absence of TGF-b were
tested as inhibitors of anti-CD3 activation of naive cells. Representative results of at least three independent experiments are shown.
(E) Splenocytes from BDC2.5/NOD mice were activated in vitro under Th1-polarizing conditions (effector population) and transferred to NOD neonatal
recipients with ActCD4 (n = 10), ActCD4TGF (n = 9), or ActTreg (n = 11) BDC2.5 T cells as inhibitor populations. Effector and inhibitor populations were
transferred at a ratio of 2:1 respectively, and recipient mice were monitored for diabetes.Foxp3sf and wild-type littermates (Chen et al., 2005). As
above, cells were stimulated with anti-CD3 anti-CD28
beads together with IL-2, in the presence or absence of
TGF-b, and gene-expression profiling was performed.
As expected, there was little divergence in the profile of
Foxp3sf and wild-type T cells from the control cultures,
but a clear difference was revealed after treatment with
TGF-b (Figure 4A).
By comparison of the TGF-b responses in CD4+ T cells
from wild-type and Foxp3sf mice, two important observa-
tions can be made (Figure 4B). First, the large number of
changes elicited by TGF-b in wild-type CD4+ T cells
remained predominantly present in Foxp3-deficient cells,
as evidenced by the probes falling within the diagonal
quadrants (Figure 4B). These include changes in a number
of transcripts that belong to the common Treg cell signa-
ture (colored highlights), indicating that TGF-b is able to in-Imduce these genes independently of Foxp3. Second, there
was an attenuation of the overall response in Foxp3sf cells,
as indicated by the offdiagonal distribution of points: In-
duced genes were generally less induced, and repressed
genes were less repressed (slope of the orthogonal linear
regression = 0.47). Thus, although Foxp3 is not absolutely
required for the bulk of gene regulation by TGF-b, its
activity seems to augment the TGF-b response.
To better appreciate the impact of Foxp3 on TGF-b-re-
sponsive genes, we calculated a ‘‘Foxp3 index’’ that indi-
cated, for each gene, the proportion of the TGF-b-induced
responses in the absence of Foxp3 relative to the full re-
sponses seen in wild-type cells; an index of 0 denotes
a TGF-b response independent of Foxp3; an index of 1 de-
notes a fully Foxp3-dependent response; and a negative
Foxp3 index value indicates antagonism between TGF-b
and Foxp3. This Foxp3 index corroborated our graphicalmunity 27, 786–800, November 2007 ª2007 Elsevier Inc. 791
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Foxp3: most TGF-b-responsive genes showed a positive
Foxp3 index, and this finding was true of genes either
induced (mean = 0.30) or repressed (mean = 0.24) by
TGF-b (Figure 4C, top panels). When the subset of TGF-
b-responsive genes belonging to the Treg signature was
considered, a similar distribution was observed (Figure 4C,
bottom panels). A smaller proportion of transcripts had
a negative Foxp3 index, indicating an antagonistic interac-
tion between Foxp3 and the TGF-b signaling pathway. We
attempted to trace the origin of these interactions by map-
ping the observed variations onto the TGF-b pathway
(Derynck and Zhang, 2003). TGF-b elicits both positive
and negative feedback on its signaling pathway: not only
upregulation of the type I receptors but also downregula-
tion of the key Smad3 transducer and induction of the
inhibitory Smurf1, Smurf2, and Smad7. Foxp3 strongly en-
hanced several of these elements, in particular the induc-
tion of the TGF-b and activin type I receptors (Figure 4F,
tabulated in Table S2). Foxp3 also repressed the TGF-
b type III receptor, which inhibits signaling by TGF-b family
members in concert with inhibins and b-arrestins (Lewis
et al., 2000; Chen et al., 2003b). Thus, the net effect of
Foxp3 might be to proximally increase sensitivity to
TGF-b signals. The minority of genes showing antagonism
between Foxp3 and the TGF-b response (negative Foxp3
index) might reflect a signaling branch that would be
particularly sensitive to inhibition by Smad7 or Smurf1.
To verify these results in another cell type, we analyzed
the response to TGF-b in CD8+ T cells, in which little to
no Foxp3 expression was induced by TGF-b treatment
(not shown), in keeping with previous observations (Kapp
et al., 2006). The TGF-b-induced signature was present
in CD8+ cells, yet muted relative to CD4+ T cells (Figure 4D),
with a good concordance between the Foxp3 indices cal-
culated by comparison of TGF-b responses of CD4+ T cells
versus Foxp3sf CD4+ cells versus CD8+ T cells (Figure 4E).
To corroborate the enhancing effect of Foxp3 on TGF-
binduced responses and begin to track its origin, we
tested the effect of FOXP3 on the nuclear and cytoplasmic
distribution of the Smad proteins, the principal mediators
of TGF-b-dependent transcriptional activity. Smad2 and
Smad3 continuously shuttle between the cytoplasm and
nucleus at steady state but are retained in the nucleus,Imand are hence transcriptionally active, after TGF-bR-
mediated phosphorylation. Smad2 and Smad3 nucleocy-
toplasmic shuttling can be regulated at multiple levels,
including TGF-b receptor activity, interactions with nu-
clear binding partners, and nuclear phosphatase activity
such as PPM1A (Hill, 2006) and is thought to be responsi-
ble for the duration and strength of TGF-b signaling. We
transfected 293 cells with a vector containing human
FOXP3 and compared by confocal microscopy the nu-
clear localization of Smad2 and Smad3 24 hr after
TGF-b stimulation. FOXP3-positive cells showed a clear
and significant bias in the distribution of nuclear Smad2
and Smad3 protein, relative to FOXP3-negative cells in
the same cultures (Figures 4G and 4H; transfection with
empty vector had no such effect—not shown). FOXP3
affected the proportion of cells with high nuclear Smad2
and Smad3, rather than the maximum level of nuclear ac-
cumulation; it also did not affect the distribution of Smad2
and Smad3 during acute TGF-b stimulation after 1 hr (data
not shown), suggesting that FOXP3 might prolong nuclear
retention rather than influx of Smad2 and 3. Thus, FOXP3
can directly influence TGF-b signaling, even in non-T cells.
Dependence of Treg Cell Signature on Foxp3
The surprising observation that TGF-b-treated cells ex-
hibited full Foxp3 expression but only some elements of
the Treg cell signature underlined the question of Foxp3’s
true contribution to the Treg cell signature. To assess this
contribution most directly, we activated purified naive
CD4+ T cells and transduced them with a retroviral vector
encoding FOXP3 and a Thy1.1 reporter. Parallel transduc-
tions were performed with vectors encoding human
FOXP3 or mouse Foxp3, and these were used for inde-
pendent corroboration. Reporter-positive cells were
sorted from these populations for gene-expression profil-
ing; as indicated, these cells were >95% Foxp3+, with
a mean fluorescence intensity almost equivalent to Treg
cells (Figure 5A).
Comparison of the profiles highlighted Foxp3’s role as a
transcriptional repressor as well as an activator, con-
sistent with previous studies (Fontenot and Rudensky,
2005; Campbell and Ziegler, 2007). When the response
to FOXP3 was compared with the Treg cell signature
(Figure 5B), it was apparent that, here again, FOXP3Figure 4. Scurfy CD4+ T Cells Show a Blunted Response to TGF-b Signaling
(A) Histogram analysis of cumulative fold-change differences between wild-type (WT) and scurfy (sf) CD4+ T cells.
(B) FcFc analysis of TGF-b signaling in WT and sf CD4+ T cells.
(C) Histogram analysis of the Foxp3 index (see Experimental Procedures) for TGF-b-responsive genes outside (top) and within (bottom) the Treg cell
signature.
(D) FcFc analysis of TGF-b signaling in CD8+ and CD4+ T cells.
(E) Histogram analysis of the Foxp3 index for TGF-b-responsive genes in CD8+ and CD4+ T cells.
(F) Pathway analysis of TGF-b signaling color coded by expression-value changes found in WT or sf CD4+ T cells (derived from ingenuity pathways
analysis, ingenuity systems).
(G) FOXP3 maintains nuclear Smad2 and Smad3 retention after TGF-b signaling. We transfected 293 cells with FOXP3 and cultured them for 24 hr in
the presence of TGF-b to determine nuclear Smad2 and Smad3 localization. A representative image of 293 cells stained with anti-Smad2/3 (red), DAPI
(blue), anti-Foxp3 (green) and the overlay of the three images are shown.
(H) Quantification of mean fluorescence intensity of nuclear Smad2 and Smad3 in Foxp3-positive or -negative cells within the same culture (as de-
picted in [G]). Representative data are shown for one of three independent experiments. Points represent nuclei that were masked individually by DAPI
staining for determination of Cy-3 (anti-Smad2/3) MFI. Horizontal bars represent the mean ± SEM; p <0.001 by Mann-Whitney test.munity 27, 786–800, November 2007 ª2007 Elsevier Inc. 793
Immunity
Regulatory T Cell Transcriptional SignatureFigure 5. Retroviral Transduction of FOXP3 in TconvCells Regulates aPopulation ofGeneswithin theCommonTregCell Signature
(A) Foxp3 expression in FOXP3-transduced cultures of activated CD4+ T cells, with Treg cells for comparison.
(B) FcFc plot comparing the effect of FOXP3 transduction with the Treg cell signature. Probes and expression values for genes in the R1-R6 regions
are found in Figures S3–S8).
(C) FcFc plot as in (B), highlighting genes whose promoter elements are bound by Foxp3 (Zheng et al., 2007; Marson et al., 2007).
(D) FcFc plot comparing the difference in gene expression between Foxp3+ Treg cells and Foxp3null Treg cells (TR/TFN data from Gavin et al. [2007] or
Lin et al. [2007]) with the TregSP profile. Gate ‘‘i’’ identifies genes whose overexpression in Treg cells requires functional Foxp3, whereas those in gate
‘‘ii’’ remain overexpressed in Treg cells in the absence of functional Foxp3 (in practice, gates were defined by the overlap between data from Gavin
et al. [2007] and Lin et al. [2007], to limit the effect of noise in these datasets); the panels at the right display the genes in gates ‘‘i’’ and ‘‘ii,’’ on the
FOXP3 transduction/Treg cell signature FcFc plot.transduction reproduced only a fraction of the Treg cell
signature. Of the transcripts overexpressed in Treg cells,
some were clearly induced by FOXP3 (188 of 407 probes
representing the consensus Treg ‘‘up’’ signature, even
with a very unrestrictive cutoff of 1.2-fold; region 2 of Fig-
ure 5B), but 180 were unaffected or even repressed (re-
gion 3). For genes underexpressed in Treg cells, the direct
effect of FOXP3 was also limited (54 of 196 probes from
the Treg ‘‘down’’ signature were repressed by FOXP3
transduction, versus 108 unaffected or even slightly
induced; regions 5 and 6). The set of transcripts directly
affected by FOXP3 included several genes considered
hallmarks of Treg cells; these genes include Il2ra, Ctla4,
Tnfrsf18, Itgae, Gpr83, and Nrp1. Treg cell transcripts
that did not respond to FOXP3 included Foxp3 itself (the
array detects the endogenous Foxp3 transcripts, not the794 Immunity 27, 786–800, November 2007 ª2007 Elsevier Inctransduced human mRNA), along with Nrn1 and Itgb8.
Conversely, FOXP3 transduction elicited changes in
a number of transcripts that do not belong to the Treg sig-
nature (regions1 and 4); these changes were reproducible,
in that many were also elicited by transduction of mouse
Foxp3 (not shown). Hence, Foxp3 alone is unable to elicit
the full range of transcriptional features of the Treg signa-
ture; in addition, it induces independent changes that do
not belong to the Treg cell signature.
Recent studies from two independent groups have used
chromatin immunoprecipitation to identify regions of ge-
nomic DNA that associate with Foxp3 in vivo (Zheng
et al., 2007; Marson et al., 2007). We thought it of interest
to compare these data with the transcriptional signature
derived here. To that end, we compiled a robust list of
the Foxp3-binding genes by applying the statistical.
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genes found in at least two conditions (combining arbitrary
cutoffs is certain to overlook some true positives, but
should yield a list of true Foxp3-binding loci with very
few false positives). These Foxp3-binding genes are high-
lighted on the plot of Figure 5C. As noted (Zheng et al.,
2007; Marson et al., 2007), many of these loci are not tran-
scriptionally responsive to FOXP3, nor do they belong to
the Treg cell signature (those at the center of Figure 5C),
but there was also an overrepresentation of transcripts
influenced by FOXP3 and/or belonging to the Treg signa-
ture (c2 p = 23 109 and 8 3 103, respectively). In addi-
tion, several Foxp3-binding loci did coincide with tran-
scripts affected by FOXP3 transduction but did not differ
in Treg versus Tconv cells (corresponding to region 1 or
region 6 of Figure 6B). Overall, the Foxp3 binding informa-
tion supported the notion that other factor(s) might com-
plement and modify, by enhancing or suppressing, the ac-
tivity of Foxp3 in generating the overall Treg cell signature.
The inability of Foxp3 to influence the expression of all
members of the Treg cell signature suggests that some
of the characteristic profile is elicited by factors other
than Foxp3. To corroborate these results, we utilized pre-
viously described datasets that were from the Rudensky
and Chatila laboratories and that compared transcripts
from normal Treg cells with those from a population of
Foxp3-negative Treg ‘‘look-alikes’’ (TFN) that appeared in
mice in which the Foxp3 coding region was replaced by
a GFP reporter (Gavin et al., 2007; Lin et al., 2007). As
illustrated in Figure 5D (left panel), the expression of
a number of transcripts characteristic of the Treg cell sig-
nature was not affected by the loss of Foxp3 in TFN cells.
Conversely, only a subset of those genes that were af-
fected by the loss of Foxp3 in the genetic-variant context
(TFN) responded to Foxp3 transduction (Figure 6D, right
panel). Thus, overlapping Foxp3-independent compo-
nents of the Treg cell signature can be demonstrated in
two independent experimental contexts.
Coregulation
To further substantiate the Foxp3 independence of certain
elements of the Treg cell signature, we made use of the
complete array of datasets and searched for correlations
between the expression of Foxp3 and other Treg cell sig-
nature genes. Our rationale was that the expression of
genes directly activated by Foxp3 might be expected to
tightly correlate with that of Foxp3 itself across the data-
sets. This was clearly the case for some transcripts,
whether positively or negatively associated with Foxp3
transcript levels (e.g., Hipk2, Pde3b; Figure 6A), but not
for all: The expression ofCtla4 correlated only very loosely
with that of Foxp3 (however, Ctla4 does correlate with
other Treg signature genes such as Swa70). This dichot-
omy is generalized in the histogram of Figure 6B, which
displays the Pearson correlation coefficient for all genes
of the Treg cell signature relative to Foxp3. Approximately
one-third of the transcripts correlated with Foxp3 (coeffi-
cient >0.5), whereas at the other end of the spectrum, some
genes exhibited the strong negative correlation expectedImfor those repressed by Foxp3 (coefficient <0.5). In be-
tween, a large number of Treg cell signature genes showed
little or no correlation with Foxp3, suggesting an indepen-
dent or at least a more complex mode of regulation.
We then determined whether other strongly correlated
clusters might be found within the Treg signature by con-
structing a complete matrix of gene-gene correlations
across all datasets and using a partition clustering algo-
rithm to group these genes into discrete clusters
(Figure 6C, cluster listings found in Table S1). These clus-
ters did show distinct expression characteristics: cluster
1, which tightly correlated with Foxp3 expression, in-
cluded a number of genes responsive to TGF-b or
FOXP3 transduction. In contrast, clusters 4 or 5 were
more directly responsive to TCR and IL-2 cues and relied
little on the presence of Foxp3. Cluster 6 was also of par-
ticular interest because many of these signature genes
were not influenced by activation, TGF-b signaling, or
FOXP3 transduction. Thus, the Treg cell signature con-
tains clusters of coexpressed genes whose regulation
does not appear directly connected to Foxp3.
Close inspection of the expression profiles of Figure 6C
revealed that, even for the genes in clusters most tightly
correlated with Foxp3, its transduction did not uniformly
lead to transactivation. We examined this relationship fur-
ther by plotting, for each gene, the correlation with Foxp3
relative to the impact of FOXP3 transduction (Figure 6D).
Several distinct groups of genes emerged. Those of
group 1 were clearly transactivated by FOXP3, yet they
correlated poorly across the grouped datasets, most
probably because they are influenced by other inducers
such as IL-2 or TGF-b (Il2ra, Socs2, and Itgae). The tran-
scripts of groups 2 and 3 all correlated well with Foxp3.
Those of group 2 were also transactivated by Foxp3, sug-
gesting that they come under Foxp3 control, direct or
indirect. In contrast, although Foxp3 correlated well with
the genes of group 3, it was unable to induce their expres-
sion (probes from groups 1–3 are found in Tables S9–S11).
This pattern of expression is what one would expect of
genes controlled by a higher-order transactivator that
would also control Foxp3. These proposed relationships
are illustrated in Figure 6E.
This study promotes the concept that a number of influ-
ences conspire to generate the Treg cell signature. Taking
the 603 genes of the by now well-defined consensus Treg
cell signature, our findings show that it is possible to dis-
tinguish those that are influenced individually by Foxp3,
TGF-b, or activation through TCR and IL-2R triggers. As
shown in Figure 6F, genes affected by IL-2 and/or TCR ac-
tivation constituted the majority of the Treg cell signature,
but many of these genes could also be influenced by
TGF-b or Foxp3. Conversely, the majority of genes re-
sponsive to Foxp3 were also responsive to another in-
ducer, either IL-2 or TGF-b. Thus, the characteristic Treg
cell signature results from a complex interplay, rather
than from any single influence. To some extent, this inter-
play is wired into the reciprocal influences that each of
these inducers has on the other’s signaling pathways:
Foxp3 and IL-2 both induce CD25, the a chain of themunity 27, 786–800, November 2007 ª2007 Elsevier Inc. 795
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Regulatory T Cell Transcriptional SignatureFigure 6. Clusters of Coregulated Genes within the Common Treg Cell Signature
(A) Expression value plots of Foxp3 versus other genes in the Treg cell signature; each dot represents an independent dataset, as listed in Figure 1A.
(B) Histogram representation of the correlation between the expression of Foxp3 and all other genes within the common Treg cell signature.
(C) Cluster analysis of expression correlations between all genes within the common Treg cell signature, clustered by a partition clustering algorithm
(k = 7). Red represents positive correlations, blue represents negative correlations, and black represents no correlation. Representative genes within
each cluster are identified to the left of the upper panel with the corresponding cluster number, see Table S1 for a full listing of genes inside the clus-
ters. The bottom portion shows a heatmap representation (for the Treg cell signature genes aligned according to their cluster membership as above)
of the differences in expression induced by FOXP3 transduction (FOXP3rv), TGF-b treatment in the presence or absence of Foxp3 (TGF and796 Immunity 27, 786–800, November 2007 ª2007 Elsevier Inc.
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expectedly, Foxp3 broadly enhances TGF-b signaling.
DISCUSSION
These results compel one to revisit the notion of Foxp3 as
a simple ‘‘master regulator’’ or ‘‘lineage-specification fac-
tor’’ for the Treg cell lineage. This transcriptional regulator
had been assigned such a role on the basis of the severe
autoimmune manifestations that appear in its absence
and on its ability to confer some degree of suppressive ac-
tivity upon retroviral transduction (Fontenot et al., 2003;
Hori et al., 2003). The very concept of ‘‘lineage-specifica-
tion factor’’ implies that such a factor be both necessary
and sufficient for the existence and phenotypic character-
istics of the lineage. Accumulating evidence, presented
here and by others, has identified circumstances in which
these two requisites are not met by Foxp3: Whether after
induction by TGF-b or after retroviral transduction, Foxp3
is not sufficient to elicit the full Treg cell signature (similarly,
activated human Tconv cells express some Foxp3, yet
show no suppressive characteristics [Walker et al., 2003;
Allan et al., 2007]). Conversely, the Rudensky and Chatila
laboratories have shown that Foxp3 is not necessary be-
cause cells with several of the characteristics of the Treg
cell lineage (including transcriptional activity at the Foxp3
locus) can be selected and persist in vivo in its absence
(Gavin et al., 2007; Williams and Rudensky, 2007; Lin
et al., 2007), consistent with the existence of Treg-like cells
in some IPEX patients (Bacchetta et al., 2006). In hindsight,
the very concept of a ‘‘lineage-specification factor’’ is likely
to be an oversimplification. It derives from the ‘‘operon’’
concept of bacterial genetics (Jacob et al., 1960); in this
concept, an entire train of genes and associated functions
are placed under the control of a single regulatory element.
But unique lineage-specification factors might not exist in
mammalian systems; some factors that might have ap-
peared at first to specify a unique lineage (such as Pax5
for B lymphocytes) were later shown to be only part of
a more complex regulatory combination (Medina and
Singh, 2005). Indeed, lineage specification in lymphoid
systems might be as dependent on the absence of an in-
hibitory factor(s) as on the presence of an inducer (Souabni
et al., 2002; Xie et al., 2004; Rothenberg and Dionne, 2002).
If not Foxp3, then what factor(s) impose the transcrip-
tional characteristics of the Treg cell lineage? One mightImhave suggested that peripheral influences expand on
a signature that is partially acquired in the thymus at the
time of lineage specification; this is clearly not the case,
because virtually all of the signature is already acquired
in thymic Treg cells, implying that the factor(s) responsible
for Treg cell generation rapidly induce a phenotype that is
actually quite robust and because the profile remains
clearly identifiable even after full TCR and IL-2 activation.
Our studies with thymic Treg cells contradict other results
suggesting that a substantially different transcriptional
profile is evident in thymic versus peripheral Treg cells
(Zheng et al., 2007; Gavin et al., 2007), but we believe that
these apparent differences are most likely to be a result
of technical differences with these previous data sets. The
coregulation analysis, demonstrating the existence of a
group of genes coregulated with Foxp3, but not induced
directly by it, suggested the presence of a higher-order
regulator, which would determine the expression of Foxp3
and of its coregulated genes. Note that this higher-order
factor need not be a single element but just as well might
be a combination of factors. In this model, Foxp3 would
then serve to transactivate an additional set of genes but
perhaps also to potentiate and reinforce the effect of the
higher-order factor (as suggested by the Rudensky labo-
ratory [Gavin et al., 2007]). There is no indication, however,
that Foxp3 transactivates its own expression in a positive
feed-forward loop, as proposed elsewhere (Gavin et al.,
2007). The set of functions directly under Foxp3 control
does include elements essential for Treg immunoregula-
tory activity, and such a finding explains why Foxp3 was
initially thought to specify the entire lineage, rather than
only a fraction of its effector characteristics.
There is clearly a complex relationship between TGF-b
and Foxp3 (and Treg cells more generally). TGF-b is inti-
mately associated with the survival and function of Treg
cells (Li et al., 2006) and can induce Foxp3 as well as a
sizable component of the Treg signature; some of this in-
duction occurs independently of Foxp3 because it is also
observed in TGF-b-treated CD8+, or Foxp3sf CD4+, cells.
Although TGF-b itself is not required for the specification
of the Treg cell lineage in the thymus, one might speculate
that signals from other members of the TGF family of cyto-
kines (for instance through activins expressed in the thy-
mus) might be required. Conversely, the present data
showed that Foxp3 enhances the response to TGF-b, at
least in part by modulating the expression of the type ITGFnoFoxp3), TCR and IL-2 activation (Act, ActIL2, and ActIL2noFoxp3), and the Treg cell signature (Treg to Tconv). Heatmaps have been row nor-
malized. Numbers between the two panels indicate the average correlation to Foxp3 expression within each cluster.
(D) Scatter plot of the changes induced by FOXP3 retroviral transduction versus the correlation coefficient values to Foxp3 for genes of the common
Treg cell signature. Box I identifies genes that can be induced by FOXP3 but are not correlated with Foxp3 expression across the dataset; box II iden-
tifies genes that are both induced by FOXP3 and show a strong correlation with Foxp3 expression. Box III contains genes that are strongly correlated
with Foxp3 but are not induced by FOXP3. See Tables S9–S11 for gene identities and values.
(E) Schematic representation of the gene-expression hierarchies derived from data within (C) and (D).
(F) Summary of genes within the common Treg cell signature whose expression can be affected by TCR and IL-2 activation (blue quadrant; defined as
>1.5-fold change in expression between wtActCD4 versus TconvSp) or TGF-b (yellow quadrant; defined as >1.5-fold change in expression between
wtActCD4TGF versus TconvSp, but <1.5-fold change between wtActCD4 versus TconvSp) or both (green quadrant, defined as >1.5-fold change in
expression between wtActCD4 versus TconvSp, and >1.5-fold change in expression between wtActCD4TGF and wtActCD4) independently of
Foxp3. Those genes whose expression can be directly regulated by FOXP3 transduction are indicated in red. Foxp3 inducible genes whose
expression can also be regulated by activation or TGF-b signaling are indicated in the red overlap of pie slices.munity 27, 786–800, November 2007 ª2007 Elsevier Inc. 797
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tion of Smad2 and Smad3. This retention could result from
a direct FOXP3-Smad interaction, as has been described
previously for FOXH1 (Randall et al., 2004) or indirectly
from a FOXP3-induced function. Although this point re-
mains to be determined, these results provide a mecha-
nism for FOXP3’s influence on TGF-b-induced transcrip-
tion.
TGF-b-induced Foxp3+ cells had little or no suppressive
ability in our hands, and their Foxp3+ status was unstable,
as also seen by others (Floess et al., 2007). In contrast,
other groups (e.g., Davidson et al. [2007]) have reported
that TGF-b-induced Foxp3+ cells have full immunoregula-
tory capacity. We surmise that subtle technical differ-
ences explain these divergent results, and it will be highly
informative to track the root of the differences because
this information should help to identify key elements of
Treg activity. Yet the key point here is that the high expres-
sion of Foxp3 present in these TGF-b-treated cells are un-
able to elicit the full Treg cell signature. Indeed, we have
observed the same genomic ‘‘hole’’ when profiling TGF-b-
converted Foxp3+ cells generated in a laboratory in which
TGF-b-Tregs do have suppressive efficacy (data not
shown; J. Hall and Y. Belkaid, personal communication).
In conclusion, our findings emphasize the need for a re-
vised view of Foxp3’s role in Treg cells. Foxp3’s relatively
minor contribution in sculpting the Treg cell transcriptional
landscape challenges the current view of this transcrip-
tion factor as a ‘‘master regulator’’ and suggests the in-
volvement of additional elements in this process. Identify-
ing this (these) factor(s) will be essential for understanding
Treg cell specification and function and their role in the
prevention of autoimmune disease.
EXPERIMENTAL PROCEDURES
Mice
NOD/LtDOI, C57BL/6J, C57Bl/6.H2g7, BDC2.5/NOD TCR tg mice
(Katz et al., 1993) and BDC/N.Foxp3sf mice (Chen et al., 2005) were
bred in our SPF Joslin facility or purchased from Jackson Laboratories
(protocol 99-20, approved by the Joslin Diabetes Center’s Interna-
tional Animal Care and Use Committee).
Cells
Treg and Tconv cells were harvested from the lymph node (inguinal,
cervical, and mesenteric from 32- to 36-week-old B6 mice), spleen
(from 6-week-old B6.H2g7 or NOD mice) or thymus (from 4- to
6-week-old BDC/N mice) for ex vivo populations. In vivo activated
and naive AND CD4+ T cells were isolated as described previously
(Obst et al., 2007). Cells used for in vitro activation were obtained
from pooled lymph node and spleen of 4- to 6-week-old BDC/N
mice or from 10-day-old BDC/N.Foxp3+ and BDC/N.Foxp3sf mice.
Cell Sorting and Flow Cytometry
For ex vivo populations, cells were sorted as B220CD8CD11bCD4+
and either CD25hi (Treg) or CD25 (Tconv). Naive cells for in vitro acti-
vation were sorted as B220CD8CD11bCD4+CD69CD62Lhi and
either CD25hi (Treg) or CD25 (Tconv). CD8 T cells for in vitro activation
were sorted as B220CD8+CD11bCD4CD69CD62Lhi. Cells from
10-day-old BDC/N.Foxp3+ and BDC/N.Foxp3sf were enriched by
anti-CD4 MACS beads. After 4 days of in vitro culture, cells were sorted
again before being processed for microarray analysis or used in func-798 Immunity 27, 786–800, November 2007 ª2007 Elsevier Inctional studies. We sorted ActCD4 and ActCD4TGF cells on CD25
positivity to ensure effective activation (top 45% for both populations).
ActTreg and ActTregTGF were also sorted as CD25 expression (>95%
CD25hi). CD8 T cells were sorted as CD8hi. Cells from wtActCD4,
wtActCD4TGF, sfActCD4, and sfActCD4TGF were all sorted as CD4+
and CD25hi (top 45%). Retrovirally transduced cells were sorted on
expression of the vector’s selectable marker (Thy1.1 or GFP). Postsort
populations were assessed for Foxp3 expression by intracellular
staining.
In Vitro Activation
T cells were activated with anti-CD3 and anti-CD28 coated beads
(Dynal) at a concentration of one bead/cell in the presence of 20 U/ml
recombinant human IL-2 (2000 U/ml for Treg cells, Proleukin, Chiron)
with or without 25 ng/ml recombinant TGF-b (Peprotech) for 4 days.
Retroviral Transduction of FOXP3
293FT cells were transfected with retroviral expression plasmids
(MSCV IRES-Thy1.1/GFP empty or encoding wild-type human or
mouse Foxp3) with TransIT-293 (Mirus) according to the manufac-
turer’s instructions. Tconv cells were activated in vitro with anti-CD3
and anti-CD28 coated beads in the presence of 20 U/ml IL-2, then
spin-infected with retrovirus supernatant at 48 hr. Cells were then cul-
tured for an additional 48 hr (total in vitro culture of 4 days).
In Vitro Inhibition Assay
A total of 13 105 BDC/N splenocytes (containing 23 104 CD4+ T cells)
were used as responders. The indicated BDC/N T cell inhibitor popu-
lations (ActCD4, ActCD4TGF, or Treg ex vivo) were cocultured at var-
ious concentrations for 4 days in the presence of 1.5 mg/ml anti-CD3
antibody ([3H] Thymidine pulse in last 18 hr). Results are averaged
from triplicate and standardized to wells with no inhibitor population.
Induction of Diabetes in NOD Neonates
We generated effector cells from BDC/N splenocytes by culturing
them in the presence of anti-CD3/CD28 beads, 20 U/ml IL-2, and
1 ng/ml IL-12 (PeproTech) for 4 days. The indicated inhibitor popula-
tions (ActCD4, ActCD4TGF, and ActTreg/ActTregTGF) were mixed
with effectors at a 1:2 ratio (0.5 3 105: 1 3 105, inhibitor: effector)
and transferred to neonatal NOD mice (1 to 3 day old).
Nuclear Localization of Smad2 and Smad3
293FT cells were transfected with retroviral expression vector contain-
ing human FOXP3 (as above). Cells were transferred to chambered
coverglass slides (Nunc) 8–24 hr later, rested for 12 hr, and cultured
with TGF-b for 24 hr. Cells were fixed and permeabilized for 2 hr; this
was followed by staining with anti-Thy1.1 FITC, rabbit anti-Smad2/3
(Cell Signaling), then by staining with donkey anti-rabbit Cy-3 (Jack-
son), anti-Foxp3 APC, and DAPI. High-power images (633) were
acquired with a Marianas microscopy workstation with Slidebook
software (3i, Denver).
Microarrays
RNA was prepared from sorted cell populations as described (Trizol
[Yamagata et al., 2004]). RNA was amplified for two rounds (Messa-
geAmp aRNA, Ambion), biotin labeled (BioArray High Yield RNA
Transcription Labeling, Enzo), and purified with the RNeasy Mini Kit
(QIAGEN). The resulting cRNAs were hybridized to M430 2.0 chips
(Affymetrix). All cell populations identified in Figure 1A were generated
in triplicate (except Foxp3rv and Ctrlrv, which were in duplicate). Raw
data were normalized with the RMA algorithm implemented in the
‘‘Expression File Creator’’ module from the GenePattern software
package (Reich et al., 2006) (www.broad.mit.edu/cancer/software/
genepattern/). We filtered probes to exclude nonvariable low- and
high-expression values by using the ‘‘Preprocess Dataset’’ module
from GenePattern and reducing the data set to 29,947 probes. Data
were visualized with the ‘‘Multiplot’’ and ‘‘SignatureDepth’’ modules
from GenePattern (R.M., unpublished data); see Supplemental.
Immunity
Regulatory T Cell Transcriptional SignatureExperimental Procedures). Gene-ontology Identifiers were curated
from www.geneontology.org. For the cluster analysis of Figure 6, a ma-
trix of correlation coefficients (6033 603 probes) was calculated for all
genes of the Treg signature, on the basis of their averaged expression
values in the 22 different conditions; this matrix was used as input for
the ‘‘clara’’ partition clustering algorithm in S-Plus.
Supplemental Data
Additional Experimental Procedures, one figure, and eleven tables
are available at http://www.immunity.com/cgi/content/full/27/5/786/
DC1/.
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